Stay updated with breaking news from Hers health. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Haemonetics (NYSE: HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently. ....
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shot up 5.8% on Wednesday . The stock traded as high as $23.47 and last traded at $23.31. 3,429,492 shares were traded during mid-day trading, a decline of 50% from the average session volume of 6,837,543 shares. The stock had previously closed at $22.04. Analyst […] ....
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) rose 5.7% on Monday after an insider bought additional shares in the company. The stock traded as high as $22.10 and last traded at $21.97. Approximately 2,810,538 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 6,811,084 shares. […] ....
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) rose 5.7% on Monday after an insider bought additional shares in the company. The company traded as high as $22.10 and last traded at $21.97. Approximately 2,810,538 shares changed hands during trading, a decline of 59% from the average daily volume of 6,811,084 […] ....
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy. ....